AVNS (Avanos Medical) LT-Debt-to-Total-Asset: 0.11 (As of Mar. 2026)

What is Avanos Medical LT-Debt-to-Total-Asset?

Avanos Medical AVNS -0.20% 62 LT-Debt-to-Total-Asset is 0.11 as of Mar. 2026. GuruFocus rates AVNS with a GF Score™ of 62/100 and a GF Value™ of $19.42 (Modestly Overvalued). The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Avanos Medical's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.11.

Avanos Medical's long-term debt to total assets ratio increased from Mar. 2025 (0.11) to Mar. 2026 (0.11). It may suggest that Avanos Medical is progressively becoming more dependent on debt to grow their business.

Avanos Medical (NYSE:AVNS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Avanos Medical LT-Debt-to-Total-Asset Related Terms

Avanos Medical LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Avanos Medical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avanos Medical LT-Debt-to-Total-Asset Chart

Avanos Medical Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.11

0.15

0.11

0.13

0.10

Avanos Medical Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.11	0.11	0.11	0.10	0.11

62GF Score

Avanos Medical Inc AVNS

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Avanos Medical LT-Debt-to-Total-Asset Calculation

Avanos Medical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	110.7	/	1073.7
	=	0.10

Avanos Medical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	117.1	/	1050.1
	=	0.11

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.11 mean?

Avanos Medical (AVNS) has a LT-Debt-to-Total-Asset of 0.11 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Avanos Medical and its competitors.

Is Avanos Medical's LT-Debt-to-Total-Asset too high?

Avanos Medical's current LT-Debt-to-Total-Asset is 0.11. Overall, Avanos Medical has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Avanos Medical's LT-Debt-to-Total-Asset compare to LMRI and AORT?

Avanos Medical's LT-Debt-to-Total-Asset of 0.11 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Avanos Medical and its competitors. Avanos Medical's current LT-Debt-to-Total-Asset is 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Avanos Medical stock overvalued right now?

Based on GuruFocus' analysis, Avanos Medical (AVNS) is currently considered Modestly Overvalued. The stock's GF Value™ is $19.42, compared to a current price of $24.88 — trading 28.1% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.11. Avanos Medical's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Avanos Medical (AVNS), the current LT-Debt-to-Total-Asset is 0.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Avanos Medical (AVNS) Overvalued in 2026?

Based on GuruFocus' analysis, Avanos Medical stock appears to be overvalued. The current stock price of $24.88 is trading 28.1% above its estimated GF Value™ of $19.42. GuruFocus considers Avanos Medical to be Modestly Overvalued.

Key valuation signals for AVNS:

LT-Debt-to-Total-Asset: 0.11
GF Value™: $19.42 vs. price of $24.88 (28.1% above fair value)
GF Score™: 62/100 with 5 warning signs

No single metric tells the full story. See the AVNS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Avanos Medical Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies LMRI AORT IRMD TNDM CNMD PRCT ENOV INSP AVR QDEL ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760

Address 5405 Windward Parkway, Suite 100 South, Alpharetta, GA, USA, 30004

Website https://www.avanos.com

Avanos Medical Inc is a medical technology company engaged in the development and commercialization of products for pain management and patient care. The company has two reportable segments: Specialty Nutrition Systems and Pain Management and Recovery. The Specialty Nutrition Systems segment provides enteral feeding and neonatal products. The Pain Management and Recovery segment offers surgical pain and recovery products, including pain pumps and radiofrequency ablation solutions for the treatment of chronic pain.

62GF Score

Get the complete analysis for AVNS

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.88

Price

$19.42

GF Value

View AVNS Analysis

See LT-Debt-to-Total-Asset data for all stocks →